| Literature DB >> 32115345 |
Miyuki Mizoguchi1, Yoshimi Matsumoto2, Ryoichi Saito3, Tomoaki Sato4, Kyoji Moriya5.
Abstract
Proper treatment of bloodstream infections requires rapid, early determination of appropriate antibiotic agents, emphasizing the need for more rapid drug susceptibility testing. The Drug Susceptibility Testing Microfluidic (DSTM) device represents a novel method in which a small amount of bacterial suspension is injected into the microchip-like device and cultured for 3 h. However, it remains unknown whether the DSTM method can directly determine antibiotic susceptibilities from positive blood cultures. Here, we developed a new approach to directly assess drug susceptibility, using the DSTM method for positive blood cultures. We compare the utility and accuracy of DSTM with those of conventional susceptibility testing methods. Fifty positive blood cultures identified as gram-negative bacilli were used herein. The outcomes of drug susceptibility and resistance assays for positive blood cultures were compared to those of conventional susceptibility testing methods to evaluate their utility and accuracy. Method agreement rates between DSTM and standard methods often exceed 90%, suggesting a high positive correlation with conventional methods. Furthermore, our results show that a combination of multiple drugs in the DSTM device helps identify extended-spectrum β-lactamase (ESBL)- and AmpC-β-lactamase (AmpC-)-producing microorganisms. In conclusion, DSTM method enables effective drug susceptibility and resistance screening within 3 h from positive blood cultures and is suitable for the rapid and personalized determination of the antimicrobial regimen.Keywords: AmpC-β-lactamase; Antibiotic susceptibility test; Blood culture; Drug susceptibility testing microfluidic device; Extended-spectrum β-lactamases
Mesh:
Substances:
Year: 2020 PMID: 32115345 DOI: 10.1016/j.jiac.2020.01.014
Source DB: PubMed Journal: J Infect Chemother ISSN: 1341-321X Impact factor: 2.211